Lumakras Patient Counseling Information

Hepatotoxicity: Advise patients to immediately contact their healthcare provider for signs and symptoms of liver dysfunction [see Hepatotoxicity under Precautions].
Interstitial Lung Disease (ILD)/Pneumonitis: Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms [see Interstitial Lung Disease (ILD)/Pneumonitis under Precautions].
Lactation: Advise women not to breastfeed during treatment with LUMAKRAS and for 1 week after the final dose [see Use in Pregnancy & Lactation].
Drug Interactions: Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, dietary and herbal products. Inform patients to avoid proton pump inhibitors, and H₂ receptor antagonists while taking LUMAKRAS [see Effects of Other Drugs on LUMAKRAS and Effects of LUMAKRAS on Other Drugs under Interactions].
If coadministration with an acid-reducing agent cannot be avoided, inform patients to take LUMAKRAS 4 hours before or 10 hours after a locally acting antacid [see Coadministration of LUMAKRAS with Acid-Reducing Agents under Dosage & Administration].
Missed Dose: If a dose of LUMAKRAS is missed by greater than 6 hours, resume treatment as prescribed the next day [see Recommended Dosage and Administration under Dosage & Administration].